Key facts
- It has raised $21.2M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Heda Ventures, China Taiping Investment, Miyin Capital, Zhejiang Jinkong Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Kanglin Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Kanglin Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kanglin Biotechnology
Developer of innovative gene therapy drugs and biopharmaceuticals intended for therapeutic purposes. The company integrates proprietary gene-editing technologies, viral vector delivery systems, scalable production processes, advanced quality assurance protocols, and clinical development frameworks, enabling global healthcare providers to address severe genetic and infectious diseases such as AIDS, Parkinson's disease, hemophilia, and thalassemia with innovative treatments that improve patient outcomes, reduce disease burden, and meet unmet medical needs through scientifically validated approaches.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2015
- Website
- kanglinbio.com/
- Ownership
- Privately Held (backing)
Kanglin Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kanglin Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kanglin Biotechnology in its N-PORT filings yet. We sweep new filings monthly.